A new injection containing the antiretroviral drug lenacapavir has demonstrated highly effective results in preventing HIV infection for six months per shot. The findings, announced by pharmaceutical company Gilead, mark a significant improvement over the current two-month protection offered by the long-acting cabotegravir (CAB-LA) injection. Lenacapavir, part of a new class of antiretroviral drugs called capsid inhibitors, works by interfering…